179 related articles for article (PubMed ID: 18192538)
21. Glucarpidase (Voraxaze) for methotrexate toxicity.
Med Lett Drugs Ther; 2012 Mar; 54(1385):19-20. PubMed ID: 22382581
[No Abstract] [Full Text] [Related]
22. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
Chen L; Greenberg WM; Brand-Schieber E; Wangsa J; Periclou A; Ghahramani P
Drug Des Devel Ther; 2015; 9():3293-300. PubMed ID: 26150701
[TBL] [Abstract][Full Text] [Related]
23. Clinical pharmacokinetics of nimodipine in normal and impaired renal function.
Kirch W; Rämsch KD; Dührsen U; Ohnhaus EE
Int J Clin Pharmacol Res; 1984; 4(5):381-4. PubMed ID: 6519852
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of ceftazidime in normal and impaired renal function.
Höffler D; Koeppe P; Williams KJ
Arzneimittelforschung; 1984; 34(1):72-6. PubMed ID: 6367755
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
26. The pharmacokinetics of antofloxacin in renally impaired rats.
Pang XY; Liu L; Zhang DM; Wang GJ; Xie L; Liu XD
J Pharm Pharmacol; 2008 May; 60(5):667-70. PubMed ID: 18416945
[TBL] [Abstract][Full Text] [Related]
27. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.
Hebert MF; Smith HE; Marbury TC; Swan SK; Smith WB; Townsend RW; Buell D; Keirns J; Bekersky I
J Clin Pharmacol; 2005 Oct; 45(10):1145-52. PubMed ID: 16172179
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
Burge DJ; Bookbinder SA; Kivitz AJ; Fleischmann RM; Shu C; Bannink J
Clin Ther; 2008 Oct; 30(10):1806-16. PubMed ID: 19014836
[TBL] [Abstract][Full Text] [Related]
30. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
Scott JR; Zhou Y; Cheng C; Ward DA; Swanson HD; Molinelli AR; Stewart CF; Navid F; Jeha S; Relling MV; Crews KR
Pediatr Blood Cancer; 2015 Sep; 62(9):1518-22. PubMed ID: 25631103
[TBL] [Abstract][Full Text] [Related]
31. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
[TBL] [Abstract][Full Text] [Related]
32. An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.
Johnson FK; Mudd PN; DiMino T; Vosk J; Sitaraman S; Boudes P; France N; Barlow C
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):256-61. PubMed ID: 27136905
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of buprenorphine following intravenous administration in dogs.
Krotscheck U; Boothe DM; Little AA
Am J Vet Res; 2008 Jun; 69(6):722-7. PubMed ID: 18518651
[TBL] [Abstract][Full Text] [Related]
34. [Clinical pharmacokinetic trial of intravenous injection of recombinant human lymphotoxin-alpha derivative].
Li S; Wang FH; Liao H; Li YH; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Dec; 25(12):1524-8. PubMed ID: 17166379
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis.
Tsaganos T; Kouki P; Digenis P; Giamarellou H; Giamarellos-Bourboulis EJ; Kanellakopoulou K
Int J Antimicrob Agents; 2008 Jul; 32(1):46-9. PubMed ID: 18534825
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.
Tisdale JE; Overholser BR; Sowinski KM; Wroblewski HA; Amankwa K; Borzak S; Kingery JR; Coram R; Zipes DP; Flockhart DA; Kovacs RJ
Pharmacotherapy; 2008 Dec; 28(12):1461-70. PubMed ID: 19025427
[TBL] [Abstract][Full Text] [Related]
37. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.
Jerling M; Abdallah H
Clin Pharmacol Ther; 2005 Sep; 78(3):288-97. PubMed ID: 16153399
[TBL] [Abstract][Full Text] [Related]
38. Glucarpidase following high-dose methotrexate: update on development.
Patterson DM; Lee SM
Expert Opin Biol Ther; 2010 Jan; 10(1):105-11. PubMed ID: 19925307
[TBL] [Abstract][Full Text] [Related]
39. A Dose-Confirmation Phase 1 Study to Evaluate the Safety and Pharmacology of Glucarpidase in Healthy Volunteers.
Fukaya Y; Kimura T; Yoshimura K; Umemura K; Kawamoto H
Clin Pharmacol Drug Dev; 2022 Mar; 11(3):364-371. PubMed ID: 34435467
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of Cefmenoxime in normal and impaired renal function.
Höffler D; Koeppe P
Arzneimittelforschung; 1983; 33(2):269-72. PubMed ID: 6303362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
